Buy And Hold Based on Artificial Intelligence: Returns up to 46.10% in 1 Month

Buy And Hold

The Fundamental Package includes our algorithmic forecasts for stocks screened by fundamental criteria. Our algorithms help you find best opportunities to buy and hold for both long and short positions for the stocks within each fundamental screen. The stocks are selected according to five basic valuation categories:

  • P/E (price to earnings ratio)
  • PEG (price/earnings to growth ratio)
  • price-to-book ratio
  • price-to-sales ratio
  • short ratio

Package Name: Fundamental – High price-to-sales ratio Stocks
Recommended Positions: Long
Forecast Length: 1 Month (02/06/2018 – 03/06/2018)
I Know First Average: 16.13%
Buy And Hold

The algorithm correctly predicted 9 out 10 of the suggested trades in the Fundamental – High price-to-sales ratio Stocks Package for this 1 Month forecast. XNCR was the highest-earning trade with a return of 46.10% in 1 Month. Additional high returns came from VEEV and WIX, at 32.72% and 32.25% respectively. The package had an overall average return of 16.13%, providing investors with a 13.14% premium over the S&P 500’s return of 2.99% during the period.

Xencor, Inc., incorporated on June 8, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company is developing a suite of clinical candidates using two of its Fc technology platforms. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.